Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

VirtualScopics, Inc., developer of image-based biomarker solutions, has announced the release if its next generation 2.0 software platform for the use of imaging in clinical trials. VirtualScopics, Inc., developer of image-based biomarker solutions, has announced the release if its next generation 2.0 software platform for the use of imaging in clinical trials.

The new platform provides FDA required 21 CFR Part 11 compliant tools for managing international imaging sites. These latest capabilities give the VirtualScopics a scalable global reach that is essential to conducting later stage clinical trials. The software platform includes a new image analysis automation system, improved traceability, enhanced tools for data management, in addition to real-time detailed reports for VirtualScopics’ customers.

“We are excited about the release of the 2.0 platform as it not only makes us more efficient in later stage clinical trials but also incorporates many features that our customers have requested relative to reporting and data mining. These enhancements provide our customers access to critical information earlier in the process, to further accelerate drug development,” said Jeff Markin, president and chief executive officer of VirtualScopics, Inc. “This software release provides a solid platform for additional planned releases that will enhance our ability to provide real-time information to our customers on a global basis.”